Major Differences in Neurooxidative and Neuronitrosative Stress Pathways Between Major Depressive Disorder and Types I and II Bipolar Disorder

被引:0
|
作者
Michael Maes
Kamila Landucci Bonifacio
Nayara Rampazzo Morelli
Heber Odebrecht Vargas
Décio Sabbatini Barbosa
André F. Carvalho
Sandra Odebrecht Vargas Nunes
机构
[1] State University of Londrina,Health Sciences Graduation Program, Health Sciences Center
[2] Chulalongkorn University,Department of Psychiatry, Faculty of Medicine
[3] Medical University of Plovdiv,Department of Psychiatry
[4] Deakin University,IMPACT Strategic Research Centre, School of Medicine
[5] University of Toronto,Department of Psychiatry
[6] Centre for Addiction & Mental Health,undefined
来源
Molecular Neurobiology | 2019年 / 56卷
关键词
Depression; Bipolar disorder; Oxidative and nitrosative stress; Immune; Inflammation;
D O I
暂无
中图分类号
学科分类号
摘要
Accumulating evidence indicates that oxidative and nitrosative stress (O&NS) pathways play a key role in the pathophysiology of bipolar disorder (BD) and major depressive disorder (MDD). However, only a handful of studies have directly compared alterations in O&NS pathways among patients with MDD and BD types I (BPI) and BPII. Thus, the current study compared superoxide dismutase (SOD1), lipid hydroperoxides (LOOH), catalase, nitric oxide metabolites (NOx), malondialdehyde (MDA), and advanced oxidation protein products (AOPP) between mood disorder patients in a clinically remitted state. To this end 45, 23, and 37 participants with BPI, BPII, and MDD, respectively, as well as 54 healthy controls (HCs) were recruited. Z-unit weighted composite scores were computed as indices of reactive oxygen species (ROS) production and nitro-oxidative stress driving lipid or protein oxidation. SOD1, NOx, and MDA were significantly higher in MDD than in the other three groups. AOPP was significantly higher in BPI than in HCs and BPII patients. BPII patients showed lower SOD1 compared to all other groups. Furthermore, MDD was characterized by increased indices of ROS and lipid hydroperoxide production compared to BPI and BPII groups. Indices of nitro-oxidative stress coupled with aldehyde production or protein oxidation were significantly different among the three patient groups (BDII > BDI > MDD). Finally, depressive symptom scores were significantly associated with higher LOOH and AOPP levels. In conclusion, depression is accompanied by increased ROS production, which is insufficiently dampened by catalase activity, thereby increasing nitro-oxidative damage to lipids and aldehyde production. Increased protein oxidation with formation of AOPP appeared to be hallmark of MDD and BPI. In addition, patients with BPII may have protection against the damaging effects of ROS including lipid peroxidation and aldehyde formation. This study suggests that biomarkers related to O&NS could aid in the differentiation of MDD, BPI, and BPII.
引用
收藏
页码:141 / 156
页数:15
相关论文
共 50 条
  • [1] Major Differences in Neurooxidative and Neuronitrosative Stress Pathways Between Major Depressive Disorder and Types I and II Bipolar Disorder
    Maes, Michael
    Bonifacio, Kamila Landucci
    Morelli, Nayara Rampazzo
    Vargas, Heber Odebrecht
    Barbosa, Decio Sabbatini
    Carvalho, Andre F.
    Vargas Nunes, Sandra Odebrecht
    MOLECULAR NEUROBIOLOGY, 2019, 56 (01) : 141 - 156
  • [2] Impulsivity in Bipolar Disorder Types I, II and Major Depressive Disorder
    Cassis, Tamara
    Iskric, Adam
    LeBaron, Nissa D.
    Low, Nancy C. P.
    BIOLOGICAL PSYCHIATRY, 2015, 77 (09) : 390S - 390S
  • [3] Differences in axis I and II comorbidity between bipolar I and II disorders and major depressive disorder
    Mantere, O
    Melartin, T
    Suominen, K
    Rytsälä, H
    Valtonen, H
    Arvilommi, P
    Leppämäki, S
    Isometsä, E
    JOURNAL OF AFFECTIVE DISORDERS, 2006, 91 : S43 - S43
  • [4] Differences in Axis I and II comorbidity between bipolar I and II disorders and major depressive disorder
    Mantere, Outi
    Melartin, Tarja K.
    Suominen, Kirsi
    Rytsälä, Heikki J.
    Valtonen, Hanna M.
    Arvilommi, Petri
    Leppämäki, Sami
    Isometsä, Erkki T.
    JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (04) : 584 - 593
  • [5] A continuity between bipolar II disorder and major depressive disorder?
    Benazzi, F
    BIOLOGICAL PSYCHIATRY, 2006, 59 (08) : 18S - 18S
  • [6] Utility of TEMPS-A in differentiation between major depressive disorder, bipolar I disorder, and bipolar II disorder
    Morishita, Chihiro
    Kameyama, Rie
    Toda, Hiroyuki
    Masuya, Jiro
    Ichiki, Masahiko
    Kusumi, Ichiro
    Inoue, Takeshi
    PLOS ONE, 2020, 15 (05):
  • [7] Lumateperone Treatment for Major Depressive Episodes With Mixed Features in Major Depressive Disorder and Bipolar I or Bipolar II Disorder
    Earley, Willie
    Durgam, Suresh
    Kozauer, Susan G.
    Chen, Changzheng
    Huo, Jason
    Stahl, Stephen
    McIntyre, Roger S.
    NEUROPSYCHOPHARMACOLOGY, 2023, 48 : 198 - 198
  • [8] LUMATEPERONE TREATMENT FOR MAJOR DEPRESSIVE EPISODES WITH MIXED FEATURES IN MAJOR DEPRESSIVE DISORDER AND BIPOLAR I OR BIPOLAR II DISORDER
    Bhagwagar, Zubin
    Kozauer, Susan G.
    Earley, Willie R.
    Chen, Changzheng
    Huo, Jason
    Stahl, Stephen
    Mcintyre, Roger S.
    Durgam, Suresh
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2025, 28 : i19 - i19
  • [9] Lumateperone treatment for major depressive episodes with mixed features in major depressive disorder and bipolar I or bipolar II disorder
    Durgam, Suresh
    Kozauer, Susan G.
    Earley, Willie R.
    Chen, Changzheng
    Huo, Jason
    Martin, Margaret
    Stahl, Stephen
    McIntyre, Roger S.
    BIPOLAR DISORDERS, 2024, 26 : 94 - 94
  • [10] Differences in incidence of suicide attempts between bipolar I and II disorders and major depressive disorder
    Holma, K. Mikael
    Haukka, Jari
    Suominen, Kirsi
    Valtonen, Hanna M.
    Mantere, Outi
    Melartin, Tarja K.
    Sokero, T. Petteri
    Oquendo, Maria A.
    Isometsa, Erkki T.
    BIPOLAR DISORDERS, 2014, 16 (06) : 652 - 661